Last reviewed · How we verify
NCT01962779: SARA
Sleep, Aging and Risk for Alzheimer's Disease
NA trial testing Continuous positive airway pressure (CPAP) in Sleep Disordered Breathing in 235 participants. Completed in 3 May 2017.
3 May 2017
Quick facts
| Lead sponsor | NYU Langone Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 235 |
| Start date | 31 July 2013 |
| Primary completion | 3 May 2017 |
| Estimated completion | 3 May 2017 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Continuous positive airway pressure (CPAP)
Conditions studied
- Sleep Disordered Breathing — all drugs for Sleep Disordered Breathing →
- Alzheimer's Disease — all drugs for Alzheimer's Disease →
Sponsor
NYU Langone Health — full company profile →
Who can join
50 and older, any sex, with Sleep Disordered Breathing or Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our preliminary data show for in cognitively-normal elderly, that Sleep Disordered Breathing (SDB) is associated with the increase of cerebrospinal fluid (CSF) phosphorylated-Tau (P-Tau) and total-Tau (T-Tau), decreases in medial temporal lobe glucose uptake (FDG-PET) and volume (MRI) and progressive memory decline, all of which have been shown to be useful in predicting future dementia in older adults. These findings raise the question as to whether Alzheimer's disease (AD) tissue damage causes SDB in the elderly, or alternatively, if SDB acts as a risk factor for AD neurodegeneration. In the proposed study, we will investigate these mechanistic hypotheses in cognitively normal elderly by examining the longitudinal associations between SDB and cognitive decline, novel MR neuroimaging and CSF biomarkers for neurodegeneration; while our secondary goal is to launch a pilot treatment study to aid in interpreting the mechanistic hypotheses and to examine the effects of nasal continuous positive airway pressure (CPAP) on cognitive decline and neurodegeneration.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects.
Osorio RS, Ducca EL, Wohlleber ME, Tanzi EB, et al · · 2016 · cited 44× · PMID 26951396 · DOI 10.5665/sleep.5846 -
Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer's disease.
Morrone CD, Raghuraman R, Hussaini SA, Yu WH. · · 2023 · cited 40× · PMID 37085942 · DOI 10.1186/s13024-023-00617-4 -
Interaction between therapeutic interventions for Alzheimer's disease and physiological Aβ clearance mechanisms.
Morrone CD, Liu M, Black SE, McLaurin J. · · 2015 · cited 23× · PMID 25999850 · DOI 10.3389/fnagi.2015.00064
Verify or expand the search:
- PubMed search for NCT01962779
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Continuous positive airway pressure (CPAP)
Trials testing the same drug.
- NCT06915831 — Type 1 Diabetes and Obstructive Sleep Apnea · NA · recruiting
- NCT07062770 — Assessment of Circuit Rebreathing During CPAP Therapy · NA · recruiting
- NCT06029959 — Stroke and CPAP Outcome Study 3 · NA · completed
- NCT05393531 — First Line Obstructive Sleep Apnea Treatment Study · Phase 4 · completed
- NCT06277115 — Acute and Long-term Effects of CPAP in OSA · NA · completed
Other recruiting trials for Sleep Disordered Breathing
Currently open trials in the same condition.
- NCT05656365 — Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA · recruiting
- NCT04118387 — Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment · Phase 4 · recruiting
- NCT05589753 — Sleep Disordered Breathing With Opioid Use · Phase 1, PHASE2 · recruiting
- NCT03858244 — Idiopathic Scoliosis Progression and Sleep-disordered Breathing in Children · active not recruiting
Other NYU Langone Health trials
Trials by the same sponsor.
- NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
- NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
- NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
- NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
- NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01962779 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
- Last refreshed: 21 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01962779.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing